IMRNWのチャート
IMRNWの企業情報
| symbol | IMRNW |
|---|---|
| 会社名 | |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | ― |
| 概要 | 事業概要 -- |
| 本社所在地 | -- |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | -- |
| 市場名 | -- |
| ipoyear | 2017年 |
| 従業員数 | - |
| url | ― |
| nasdaq_url | https://www.nasdaq.com/symbol/imrnw |
| adr_tso | ― |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 2.5 |
| 時価総額（marketcap） | 0 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
IMRNWのテクニカル分析
IMRNWのニュース
Australian biotech Immuron appoints CEO 2022/05/06 09:16:46 Seeking Alpha
Australia-based Immuron (IMRN) appointed Steven Lydeamore as CEO, effective June 27.The company said Lydeamore recently served as CEO of Anatara Lifesciences.Immuron (IMRN) added…
Immuron Travelan Global sales up 216% 2022/04/27 10:00:00 Wallstreet:Online
Key Highlights: North American Travelan sales up by 185% YoY in Q3 FY22 Global sales up 216% YoY in Q3 FY22. YTD March 31, FY22 worldwide Travelan sales reached AU $392K, increasing 340% YoY. MELBOURNE, Australia, April 27, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics
Immuron new MTEC project proposal "Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease" 2022/04/19 11:33:47 Benzinga
Key Highlights: Immuron''s request for AU$5.4M (US$4M) additional funding from the U.S. Department of Defense for Travelan considered to be ‘eligible for award'' Travelan Investigational New Drug (IND) application advances Clinical trial Synopsis complete and plans in place to conduct a controlled human infection model (CHIM) clinical trial in 60 healthy volunteers in the USA MELBOURNE, Australia, April 19, 2022 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ: IMRN ), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to advise that a new request for funding has been considered to be eligible for award by the US Department of Defense funding body ‘Medical Technology Enterprise Consortium'' (MTEC). Immuron is pursuing a regulatory pathway to license Travelan ® with the Food and Drug Administration (FDA) via a Biologics License Application (BLA). The proposed indication is to reduce the risk of contracting travelers'' diarrhea caused by bacterial pathogens.
Immuron gains on tax concession cash refund from Australian Government (NASDAQ:IMRN) 2022/01/18 19:07:25 Seeking Alpha
Immuron <> ADRs have approached the highest level in more than three months after announcing a cash refund of approximately AUD 306K from the Australian government.The refund was…
Immuron secures European Patent on drug composition for travelers diarrhea 2022/01/13 11:36:19 Seeking Alpha
Immuron (IMRN) has been granted a European Patent for compositions and methods for treating travelers diarrhea
Australian biotech Immuron appoints CEO 2022/05/06 09:16:46 Seeking Alpha
Australia-based Immuron (IMRN) appointed Steven Lydeamore as CEO, effective June 27.The company said Lydeamore recently served as CEO of Anatara Lifesciences.Immuron (IMRN) added…
Immuron Travelan Global sales up 216% 2022/04/27 10:00:00 Wallstreet:Online
Key Highlights: North American Travelan sales up by 185% YoY in Q3 FY22 Global sales up 216% YoY in Q3 FY22. YTD March 31, FY22 worldwide Travelan sales reached AU $392K, increasing 340% YoY. MELBOURNE, Australia, April 27, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics
Immuron new MTEC project proposal "Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease" 2022/04/19 11:33:47 Benzinga
Key Highlights: Immuron''s request for AU$5.4M (US$4M) additional funding from the U.S. Department of Defense for Travelan considered to be ‘eligible for award'' Travelan Investigational New Drug (IND) application advances Clinical trial Synopsis complete and plans in place to conduct a controlled human infection model (CHIM) clinical trial in 60 healthy volunteers in the USA MELBOURNE, Australia, April 19, 2022 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ: IMRN ), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to advise that a new request for funding has been considered to be eligible for award by the US Department of Defense funding body ‘Medical Technology Enterprise Consortium'' (MTEC). Immuron is pursuing a regulatory pathway to license Travelan ® with the Food and Drug Administration (FDA) via a Biologics License Application (BLA). The proposed indication is to reduce the risk of contracting travelers'' diarrhea caused by bacterial pathogens.
Immuron gains on tax concession cash refund from Australian Government (NASDAQ:IMRN) 2022/01/18 19:07:25 Seeking Alpha
Immuron <> ADRs have approached the highest level in more than three months after announcing a cash refund of approximately AUD 306K from the Australian government.The refund was…
Immuron secures European Patent on drug composition for travelers diarrhea 2022/01/13 11:36:19 Seeking Alpha
Immuron (IMRN) has been granted a European Patent for compositions and methods for treating travelers diarrhea
Australian biotech Immuron appoints CEO 2022/05/06 09:16:46 Seeking Alpha
Australia-based Immuron (IMRN) appointed Steven Lydeamore as CEO, effective June 27.The company said Lydeamore recently served as CEO of Anatara Lifesciences.Immuron (IMRN) added…
Immuron Travelan Global sales up 216% 2022/04/27 10:00:00 Wallstreet:Online
Key Highlights: North American Travelan sales up by 185% YoY in Q3 FY22 Global sales up 216% YoY in Q3 FY22. YTD March 31, FY22 worldwide Travelan sales reached AU $392K, increasing 340% YoY. MELBOURNE, Australia, April 27, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics
Immuron new MTEC project proposal "Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease" 2022/04/19 11:33:47 Benzinga
Key Highlights: Immuron''s request for AU$5.4M (US$4M) additional funding from the U.S. Department of Defense for Travelan considered to be ‘eligible for award'' Travelan Investigational New Drug (IND) application advances Clinical trial Synopsis complete and plans in place to conduct a controlled human infection model (CHIM) clinical trial in 60 healthy volunteers in the USA MELBOURNE, Australia, April 19, 2022 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ: IMRN ), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to advise that a new request for funding has been considered to be eligible for award by the US Department of Defense funding body ‘Medical Technology Enterprise Consortium'' (MTEC). Immuron is pursuing a regulatory pathway to license Travelan ® with the Food and Drug Administration (FDA) via a Biologics License Application (BLA). The proposed indication is to reduce the risk of contracting travelers'' diarrhea caused by bacterial pathogens.